Compared to the general population, older adults are more at risk of experiencing adverse drug reactions. Why is this the case, and what does this mean for pharmacovigilance?

In focus / 29 October 2024

Pharmacovigilance monitors the safety of the medicines we use, but what about those that get into our environment?

In focus / 15 October 2024

EcoPV aims to monitor and manage the environmental impact of pharmaceuticals. How may we best support this effort?

In focus / 01 September 2024

Our genes contribute anything from 15 to 95% of how we react to medicines. Why is this the case, and when is genetic testing necessary to avoid the risk of potential side effects?

In focus / 21 August 2024